Brainstorm Cell Therapeutics Stock Investor Sentiment

BCLI Stock  USD 1.74  0.12  7.41%   
Under 55% of Brainstorm Cell's traders are presently thinking to get in. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that some traders are interested. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
  

Brainstorm Cell Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two weeks ago at thelincolnianonline.com         
Brainstorm Cell Therapeutics Inc. Short Interest Update
news
over two weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeutics Inc
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate U...
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
Macroaxis News
over two weeks ago at news.google.com         
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing - Yaho...
Google News at Macroaxis
over a month ago at seekingalpha.com         
BrainStorm Cell Therapeutics regains compliance with Nasdaq
seekingalpha News
over a month ago at finance.yahoo.com         
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn Expanded Access Program at...
Yahoo News
over a month ago at thelincolnianonline.com         
Brainstorm Cell Therapeutics Inc. Short Interest Up 33.1 percent in October
news
over a month ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Brainstorm Cell Therapeutics Research Coverage Started at StockNews.com
news
over a month ago at www.macroaxis.com         
Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn Trial at the 2024 Maxim ...
Yahoo News
over two months ago at investing.com         
Brainstorm cell therapeutics CEO acquires 11,308 in stock
Investing News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Brainstorm Cell that are available to investors today. That information is available publicly through Brainstorm media outlets and privately through word of mouth or via Brainstorm internal channels. However, regardless of the origin, that massive amount of Brainstorm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Brainstorm Cell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Brainstorm Cell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Brainstorm Cell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Brainstorm Cell alpha.

Brainstorm Cell Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
09/16/2024
2
Brainstorm Cell Therapeutics Research Coverage Started at StockNews.com
09/27/2024
3
Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3
09/30/2024
4
Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3
10/01/2024
5
Brainstorm cell therapeutics CEO acquires 11,308 in stock
10/02/2024
6
Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3
10/10/2024
7
Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3
10/11/2024
8
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn Expanded Access Program at 2024 Annual NEALS Meeting
10/28/2024
9
Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
11/12/2024

Complementary Tools for Brainstorm Stock analysis

When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Global Correlations
Find global opportunities by holding instruments from different markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences